New combo aims to keep cancer in check with fewer side effects
NCT ID NCT03264547
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tested whether a combination of eribulin, pertuzumab, and trastuzumab works as well as the standard taxane-based combo for advanced HER2-positive breast cancer, but with better quality of life. 446 women who had not received chemotherapy for advanced disease took part. The goal was to see if the new combo could control the cancer for a similar amount of time while reducing side effects like numbness and tingling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanagawa Cancer Center
Yokohama, Kanagawa, 241-8515, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, Osaka, 540-0006, Japan
Conditions
Explore the condition pages connected to this study.